RxDoctor Payments DataLook up a doctor →

Annette Okai, MD

Neurology · Plano, TXNPI 1275755399

Payments from drug & device makers

$4,147,768in general payments, 2019–2025

Across 1,886 payments — averaging $2199.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.7M
  • Novartis$935K
  • Sanofi$531K
  • AstraZeneca$161K
  • Biogen$155K
  • Genentech USA, Inc.$107K
  • plus $511K from 53 others
$28,205in research payments, 2019–2025

Across 29 payments — averaging $972.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$14K
  • F. Hoffmann-la Roche AG$6K
  • Novartis Pharma AG$5K
  • Sanofi$2K
  • Sanofi US Services Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.155$1,746,764
Novartis74$935,452
Sanofi225$530,693
AstraZeneca133$160,977
Biogen219$155,320
Genentech USA, Inc.170$107,431
TG Therapeutics, Inc.49$103,293
F. Hoffmann-la Roche AG27$102,250
EMD Serono, Inc.220$90,593
Bristol Myers Squibb102$80,586
Merck Kgaa15$61,834
Modernatx, Inc.7$24,268
E.r. Squibb & Sons, L.L.C.8$12,903
Teva Pharmaceuticals USA, Inc.24$12,618
Amgen(2 entities)77$6,322
Greenwich Biosciences, Inc.7$3,677
Sanofi-aventis U.S. LLC6$3,582
Invivyd Inc1$2,135
AbbVie(2 entities)70$1,317
Merz Pharmaceuticals, LLC21$738
Ipsen Biopharmaceuticals, Inc42$733
Axsome Therapeutics, Inc.25$542
Lundbeck LLC18$384
Lilly USA, LLC26$359
Avanir Pharmaceuticals, Inc.35$291
Scilex Pharmaceuticals Inc.15$276
UCB, Inc.10$219
Biohaven Pharmaceutical Holding Company Ltd.12$195
Biohaven Pharmaceuticals, Inc.7$193
Grifols USA, LLC9$165
Pfizer8$143
Sanofi US Services Inc.3$137
Argenx US, Inc.5$134
Mallinckrodt Enterprises LLC8$128
Acorda Therapeutics, Inc5$104
Upsher-smith Laboratories LLC4$99
Inspire Medical Systems, Inc.2$95
Harmony Biosciences LLC5$82
Otsuka America Pharmaceutical, Inc.4$81
Jazz Pharmaceuticals Inc.2$71
Johnson & Johnson(2 entities)3$67
Impel Pharmaceuticals Inc.4$60
Acadia Pharmaceuticals Inc2$45
Abbott2$44
Banner Life Sciences, LLC2$41
Tonix Medicines, Inc.2$40
SK Life Science, Inc.1$38
Shire North American Group Inc2$31
Sumitomo Pharma America, Inc.2$28
Akcea Therapeutics, Inc.1$27
Vertex1$25
Arbor Pharmaceuticals, Inc.2$24
Supernus Pharmaceuticals, Inc.1$21
GRT US Holding, Inc.1$19
Impel Pharmaceuticals LLC1$18
Amneal Pharmaceuticals LLC1$18
Azurity Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$14
Kyowa Kirin, Inc.1$13

How this compares

$4,147,768 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$291,814
Medicare patients
63
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Plano

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →